clinical Information

    • DRAMP ID

    • DRAMP18068

    • Sequence

    • GRRRRSVQWCA

    • Sequence Name

    • hLF1-11

    • Description

    • an 11-mer peptide from the N terminus of human lactoferrin

    • Activity

    • Antibacterial, Antifungal

    • Medical use

    • LPS-mediated diseasesand fungal infections

    • Stage of Development

    • Phase I(Completed)

    • Comments

    • hLF1-11 has proved efficacious in animal models of osteomyelitis and other bacterial infections.Significant efficacy observed in Phase I trials; mechanism of action appears to be immunomodulatory rather than antibiotic.

    • Company

    • AM-Pharma Holding BV

    • Target Organism

      • In vivo,a dose-dependent bacteriocidal effect of intravenous administered peptide was observed in both immunocompetent and -compromised mice with a MRSA infection and hLF1-11 0.4–40µg/kg reduced 2 – 3 logs of bacterial counts in mice

    • Reference

      • Comparable efficacies of the antimicrobial peptide human lactoferrin 1–11 and gentamicin in a chronic methicillin-resistantStaphylococcus aureusosteomyelitis model. Antimicrob. Agents Chemother.(2005).(PMID: 15917544)
      • Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect. Immun.(2001)(PMID: 11179314)
      • The high effective antimicrobial peptide hLF (1-11) may be given to (immunocompromised) mice with a multidrug resistant Staphylococcus aureusinfection by various routes. 45th Interscience Conference on Antimicrob. Agents Chemother.Washington DC, USA (2005)